Fredrik E.
- Country
- Sweden
- Department
- Department of Internal Medicine
Research Overview
- Phase II Study of ME-401 with Rituximab-Bendamustine for High-Risk and Rituximab with ME-401 Randomization for Low-Risk Follicular Lymphoma Treatment
- Evaluation of Acalabrutinib and Rituximab in Elderly Patients with Untreated Mantle Cell Lymphoma: A Clinical Trial Analysis
- Phase II Study of Rituximab, Lenalidomide, and Tafasitamab in High-Risk Follicular Lymphoma and Rituximab, Lenalidomide with Tafasitamab Randomization in Low-Risk Cases
Data & Insights
Has run more than one trial at 20 of 59 partner sites.
Specializations
Lymphoma Treatment Research
This investigator specializes in the treatment of various lymphoid malignancies, with particular emphasis on novel therapeutic approaches for different lymphoma subtypes.
- Mantle Cell Lymphoma (MCL) therapy development
- Follicular Lymphoma treatment optimization
- Diffuse Large B-Cell Lymphoma management
The focus includes innovative combination therapies using targeted agents and immunotherapy.
Immunotherapy Applications
The investigator explores various immunotherapeutic approaches in lymphoma treatment, particularly focusing on antibody-based therapies.
- Rituximab-based combination treatments
- Novel antibody therapeutics integration
- Immunomodulatory treatment strategies
Research encompasses both high-risk and low-risk disease management scenarios.
Treatment Innovation
The investigator develops innovative therapeutic combinations for lymphoma treatment, incorporating both established and emerging medications.
- Combined modality approaches
- Risk-adapted treatment strategies
- Novel drug combination assessment
Research includes evaluation of treatment efficacy in various patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.